Compare SiTime Corporation (SITM) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SiTime Corporation vs Sanofi SA — how do they compare? SiTime Corporation trades at $685 (market cap $20.05B), while Sanofi SA trades at $43.6 (market cap $104.30B). The key difference: Sanofi SA is far larger — about 5.2× SiTime Corporation's market cap, and Sanofi SA pays a 5.55% dividend while SiTime Corporation pays none. Which is the better fit depends on your goals.
| SITM | SNY | |
|---|---|---|
Market Cap | $20.05B | $104.30B |
Sector | Technology | Health |
52-Week High | $901.60 | $52.34 |
52-Week Low | $212.77 | $41.33 |
Enterprise Value | $19.45B | $124.19B |
Dividend Yield | — | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SITM trades at $680.52, down 1.37% on the day, with a bullish technical outlook supported by moving averages and key resistance at $687. The company reported strong Q2 2026 earnings of $2.34 per share, beating estimates, with revenue surging 127% year-over-year driven by AI infrastructure demand. Analyst consensus is unanimously bullish with a $870 price target, reflecting optimism around the Renesas acquisition and AI timing growth.
The outlook for SITM is positive given robust earnings beats, AI-driven revenue expansion, and solid institutional support. However, risks include premium valuation multiples, integration challenges from the Renesas deal, and dependence on cyclical tech spending. Investors should weigh high growth potential against execution risks in a competitive semiconductor market.
SNY trades at $43.62, up 0.32% today, with a neutral technical signal and bullish moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 outlook. Revenue for 2025 was $46.72B with net income of $7.81B, showing improved profitability. Analyst consensus is mixed with 44% Buy, 52% Hold, and 4% Sell ratings. Recent news highlights regulatory approvals for new drugs and pipeline developments under new CEO leadership.
The outlook for SNY is cautiously optimistic, driven by Dupixent's growth and new drug approvals, but faces risks from pipeline setbacks and competition. Earnings momentum and cost discipline support upside potential, though valuation multiples like a P/E of 23.27 may limit near-term gains. Key risks include biosimilar threats post-2031 and ongoing legal challenges. Institutional activity shows increased holdings, reflecting confidence in the company's strategic direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SiTime Corporation
SiTime Corporation is a leading provider of MEMS-based silicon timing solutions used in various electronic applications. The company’s products, including oscillators, resonators, and clock ICs, are designed to replace traditional quartz-based timing devices, offering superior performance, reliability, and smaller size in harsh environments. SiTime's solutions are adopted across high-growth markets such as 5G, data centers, industrial IoT, and automotive, positioning the company as a key enabler for next-generation electronic systems.
Read more on SITM →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
